Mina Sooch News Today

Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its fourth-quarter and year-end financial results on March 30

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy after 24 Weeks of Treatment Oral... | January 25, 2023

Nyxol demonstrated positive topline results in subjects with night vision disturbances in the phase 3 LYNX-1 pivotal clinical trial, Ocuphire Pharma announced in a press release.One hundred forty-five subjects who experienced night vision impairment were randomly assigned to receive either Nyxol (0.75% phentolamine ophthalmic solution) or placebo daily for 14 days. The primary endpoint was the

NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early...

FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...

FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication - read this article along with other careers information, tips and advice on BioSpace

Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo ...

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances - read this article along with other careers information, tips and advice on BioSpace

GuruFocus Article or News written by GuruFocusNews and the topic is about: